Nurix Therapeutics Inc. (NRIX)
Company Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders.
The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer.
The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018.
The company was incorporated in 2009 and is headquartered in San Francisco, California.

Country | United States |
IPO Date | Jul 24, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 286 |
CEO | Dr. Arthur T. Sands M.D., Ph.D. |
Contact Details
Address: 1700 Owens Street San Francisco, California United States | |
Website | https://www.nurixtx.com |
Stock Details
Ticker Symbol | NRIX |
Exchange | NASDAQ |
Fiscal Year | December - November |
Reporting Currency | USD |
CIK Code | 0001549595 |
CUSIP Number | 67080M103 |
ISIN Number | US67080M1036 |
Employer ID | 27-0838048 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Arthur T. Sands M.D., Ph.D. | Chief Executive Officer, President & Director |
Johannes Van Houte | Chief Financial Officer |
Buckley Kohlhauff | Senior Vice President of Information Technology |
Christopher B. Phelps Ph.D. | Senior Vice President & Head of Early Drug Discovery |
Dr. Bev Benson Ph.D. | Vice President & Head of Clinical Science |
Dr. Eren Demirhan Ph.D. | Vice President & Head of Biometrics |
Dr. Gwenn M. Hansen Ph.D. | Chief Scientific Officer |
Dr. Jason Kantor Ph.D. | Chief Business Officer |
Dr. Marine Champsaur Ph.D. | Vice President & Head of Medical Affairs |
Dr. Paula G. O'Connor M.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2025 | DEFA14A | Filing |
Mar 28, 2025 | ARS | Filing |
Mar 28, 2025 | DEF 14A | Filing |
Mar 13, 2025 | 4 | Filing |
Mar 13, 2025 | 3 | Filing |
Mar 13, 2025 | 8-K | Current Report |
Mar 03, 2025 | 4 | Filing |
Feb 14, 2025 | SCHEDULE 13G | Filing |
Feb 14, 2025 | SCHEDULE 13G | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |